Lunit highlights Karolinska AI studies
Lunit is claiming that its artificial intelligence (AI) algorithm showed grea...Read more on AuntMinnie.comRelated Reading: Lunit partners with Philips on chest AI software Lunit, Infinitt partner on Indonesian distribution deal Lunit touts study for COVID-19 imaging Lunit highlights AI lung cancer detection research Lunit touts AI mammography studies (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 16, 2021 Category: Radiology Source Type: news

NLR May Be Tied to Survival in Patients With NSCLC Brain Metastases NLR May Be Tied to Survival in Patients With NSCLC Brain Metastases
In patients with non-small cell lung cancer brain metastases treated with immune-checkpoint inhibitors and upfront steroids, a low NLR was associated with lower overall survival.Reuters Health Information (Source: Medscape Radiology Headlines)
Source: Medscape Radiology Headlines - April 16, 2021 Category: Radiology Tags: Hematology-Oncology News Source Type: news

CT radiomics predicts survival in NSCLC patients
CT radiomics can be useful for predicting survival in patients receiving immunotherap...Read more on AuntMinnie.comRelated Reading: How higher radiation stacks up when treating lung cancer Radiomics, AI can guide NSCLC treatment decisions Radiomics can aid management of lung cancer patients PET shows promise for detecting NSCLC recurrence Radiomics can predict treatment outcome for NSCLC (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 16, 2021 Category: Radiology Source Type: news

Survival Benefit and Toxicity of Icotinib for EGFR+ NSCLC Survival Benefit and Toxicity of Icotinib for EGFR+ NSCLC
Might the use of adjuvant icotinib improve survival among EGFR mutation-positive NSCLC patients? What do we know about the treatment-related toxicities?Translational Lung Cancer Research (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - April 15, 2021 Category: Consumer Health News Tags: Hematology-Oncology Journal Article Source Type: news

AI predicts heart disease mortality from CT lung screening exams
A deep-learning algorithm used to analyze CT lung cancer screening exams wa...Read more on AuntMinnie.comRelated Reading: Shared decision-making: Is it harmful for lung cancer screening? ACR urges Aetna to update lung cancer screening policy How can access to CT lung cancer screening be improved? Medicare urged to update lung cancer screening coverage ACR praises USPSTF's lung cancer screening changes (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 15, 2021 Category: Radiology Source Type: news

PET shows slow cognitive recovery in chronic COVID-19 patients
FDG-PET scans and cognitive function tests showed that patients with chroni...Read more on AuntMinnie.comRelated Reading: COVID-19 has had dramatic impact on breast imaging FDG-PET/CT effective for staging in new breast cancer When will PET/MRI live up to its promise? AI reduces FDG dose on PET imaging Radiomics can aid management of lung cancer patients (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 15, 2021 Category: Radiology Source Type: news

McMaster scientists discover trained immune cells are highly effective against cancer
(McMaster University) McMaster University researchers Ali Ashkar and Sophie Poznanski have uncovered that changing the metabolism of natural killer (NK) immune cells allows these cells to overcome the hostile conditions found inside tumours and destroy advanced ovarian and lung cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 15, 2021 Category: Cancer & Oncology Source Type: news

Lung cancer screening predicts risk of death from heart disease
(Radiological Society of North America) A deep learning algorithm accurately predicts the risk of death from cardiovascular disease using information from low-dose CT exams performed for lung cancer screening, according to a new study. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 15, 2021 Category: Cancer & Oncology Source Type: news

Immunotherapy alone extended life for metastatic lung cancer patients with KRAS mutation
(University of Pennsylvania School of Medicine) Real-word evidence is suggesting, for the first time, the most beneficial treatment courses that could help extend the lives of patients with metastatic non-small cell lung cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 15, 2021 Category: Cancer & Oncology Source Type: news

expanded-collaboration-MD-Anderson
Boehringer Ingelheim and MD Anderson Expand Collaboration to Accelerate Development of KRAS and TRAILR2 Compounds in Lung Cancer  Agreement builds on successful preclinical studies in gastrointestinal cancers through the joint Virtual Research and Development Center (VRDC)  The continued collaboration will explore lung cancer targeting KRAS and TRAILR2 molecules from Boehringer Ingelheim ’s growing portfolio of cancer treatments and builds on its commitment to delivering first-in-class treatment options to people living with cancer  (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - April 14, 2021 Category: Research Source Type: news

Shared decision-making: Is it harmful for lung cancer screening?
Why is CT lung cancer screening the only screening exam to require a sessio...Read more on AuntMinnie.comRelated Reading: Medicare urged to update lung cancer screening coverage USPSTF's new lung cancer screening guidance lowers starting age How useful is shared decision-making for lung cancer screening? How high are complication rates from CT lung screening? Video beats brochure to prep smokers for CT screening (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 14, 2021 Category: Radiology Source Type: news

Set of genetic markers in lung cancer identified
(Wake Forest Baptist Medical Center) Investigators at Wake Forest School of Medicine, part of Wake Forest Baptist Health, have identified a set of new genetic markers that could potentially lead to new personalized treatments for lung cancer. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 14, 2021 Category: Biology Source Type: news

MD Anderson and Boehringer Ingelheim expand collaboration to accelerate development of KRAS and TRAILR2 compounds in lung cancer
(University of Texas M. D. Anderson Cancer Center) MD Anderson and Boehringer Ingelheim have expanded their joint Virtual Research and Development Center to accelerate the development of new targeted therapies against KRAS and TRAILR2 in lung cancer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 14, 2021 Category: Cancer & Oncology Source Type: news

Health Highlights: April 13, 2021
Drug/Chemo Combo May Help Lung Cancer Patients: Study A combination of the immune-boosting drug Opdivo and chemotherapy appears to benefit some lung cancer patients before surgery, according to a new study. The clinical trial involving about 350... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 13, 2021 Category: General Medicine Source Type: news

ACR releases clinical imaging research registry
The American College of Radiology (ACR) has released a clinical image researc...Read more on AuntMinnie.comRelated Reading: ACR urges Aetna to update lung cancer screening policy ACR calls JAMA breast cancer article 'misleading' ACR praises USPSTF's lung cancer screening changes ACR Data Science Institute expands list of AI use cases ACR DSI enables searching for FDA-cleared AI algorithms (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 12, 2021 Category: Radiology Source Type: news

Immune-boosting drug may help before lung cancer surgery
Doctors say that a drug that boosts the immune system may help before lung cancer surgery (Source: ABC News: Health)
Source: ABC News: Health - April 12, 2021 Category: Consumer Health News Tags: Health Source Type: news

Drug testing approach uncovers effective combination for treating small cell lung cancer
Scientists targeted a vulnerability in how the cancer cells reproduce. (Source: National Institutes of Health (NIH) News Releases)
Source: National Institutes of Health (NIH) News Releases - April 12, 2021 Category: American Health Source Type: news

Presurgical Nivo/Chemo Boosts pCR Rates in NSCLC Presurgical Nivo/Chemo Boosts pCR Rates in NSCLC
For patients with resectable non –small cell lung cancer (NSCLC) tumors, adding immunotherapy to platinum-based chemotherapy improved pathologic complete response (pCR) rates.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 12, 2021 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Latest KCIC Report Finds Decline in Mesothelioma Lawsuits
The number of mesothelioma lawsuits filed in 2020 dropped significantly, while cases involving lung cancer continued to increase, according to a recent study reflecting the changing face of asbestos litigation. KCIC, a well-respected consulting firm in Washington, D.C., that manages asbestos product liabilities, released its industry report Thursday. Asbestos legal filings, covering both malignant and nonmalignant disease in the United States, dropped 11% from 2019 to 2020, from 4,137 to 3,685 cases, respectively. Most prominently, there was a 9% increase in asbestos-related lung cancer filings, but a 14% decrease...
Source: Asbestos and Mesothelioma News - April 12, 2021 Category: Environmental Health Authors: Amy Edel Source Type: news

AI and immunotherapy: Taking the next step
(Case Western Reserve University) Researchers from Case Western Reserve University, New York University (NYU), and University Hospitals in Cleveland have been awarded a five-year, $3 million National Cancer Institute grant to develop and apply AI tools for predicting which lung cancer patients will respond to immunotherapy. This is first time they'll test those tools during an ongoing clinical trial, the next step toward their own clinical trials that would allow physicians to apply the tools with participating patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 12, 2021 Category: International Medicine & Public Health Source Type: news

Drug testing approach uncovers effective combination for treating small cell lung cancer
(NIH/National Center for Advancing Translational Sciences (NCATS)) NIH researchers have identified and tested a drug combination that exploits a weakness in small cell lung cancer, an aggressive cancer. They targeted a vulnerability in cancer cell reproduction, increasing replication stress ¬ ¬ -- a hallmark of out-of-control cell growth in many cancers that damages DNA and forces cancer cells to constantly repair themselves. In a small trial, the drug duo shrank tumors in SCLC patients. The team's findings appear April 12 in Cancer Cell. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 12, 2021 Category: Cancer & Oncology Source Type: news

Level of chromosomal abnormality in lung cancer may predict immunotherapy response
(Dana-Farber Cancer Institute) Patients with non-small cell lung cancer (NSCLC) whose cancer cells have low levels of aneuploidy - an abnormal number of chromosomes - tend to respond better to immune checkpoint inhibitor drugs than patients with higher levels, Dana-Farber Cancer Institute researchers will report at the virtual AACR Annual Meeting 2021. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 10, 2021 Category: Cancer & Oncology Source Type: news

ACR urges Aetna to update lung cancer screening policy
The American College of Radiology (ACR) is urging Aetna to update its lung cance...Read more on AuntMinnie.comRelated Reading: How can access to CT lung cancer screening be improved? Medicare urged to update lung cancer screening coverage ACR praises USPSTF's lung cancer screening changes USPSTF's new lung cancer screening guidance lowers starting age ACR Data Science Institute expands list of AI use cases (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 9, 2021 Category: Radiology Source Type: news

FDA D.I.S.C.O. Burst Edition: Lorbrena (lorlatinib) for patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive, detected by an FDA-approved test
Listen to a soundcast of the March 3, 2021 approval of Lorbrena (lorlatinib) for patients with metastatic non-small cell lung cancer whose tumors are anaplastic lymphoma kinase-positive, detected by an FDA-approved test. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - April 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news

National nonprofits launch cancer screening campaign in COVID-19 era
The Community Oncology Alliance and CancerCare, two national nonprofit advocac...Read more on AuntMinnie.comRelated Reading: Breast cancer incidence to increase by 2040, but not mortality How can access to CT lung cancer screening be improved? ASTRO survey finds rise in advanced-stage cancer CT exam encounters could boost colorectal cancer screening Cancer screenings drop precipitously due to COVID-19 (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 8, 2021 Category: Radiology Source Type: news

Changes in Cancer Incidence, Deaths Expected by 2040
THURSDAY, April 8, 2021 -- Cancer incidence and death are expected to change by 2040, with breast cancer remaining the most common cancer followed by melanoma, then lung cancer, according to a study published online April 7 in JAMA Network... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 8, 2021 Category: Pharmaceuticals Source Type: news

A new treatment for metastatic lung cancer
(University of Colorado Anschutz Medical Campus) A new phase 3 randomized clinical trial overseen by CU Cancer Center member Chad Rusthoven, MD, and Vinai Gondi, MD, from Northwestern University, is testing whether a new treatment approach could result in improved outcomes for patients with small cell lung cancer (SCLC) that has spread to the brain. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - April 8, 2021 Category: Cancer & Oncology Source Type: news

Breast cancer incidence to increase by 2040, but not mortality
Breast cancer incidence will likely grow over the next two decades in the U.S....Read more on AuntMinnie.comRelated Reading: Falling lung cancer rates drive cancer decline in U.S. Cancer caused 4M years of lost life in U.S. New treatments lead to drop in lung cancer deaths Medicaid expansion under ACA linked to fewer cancer deaths Cancer deaths decline in the U.S. (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - April 7, 2021 Category: Radiology Source Type: news

Why So Many New Cancer Diagnoses When Americans Turn 65?
WEDNESDAY, April 7, 2021 -- A few years ago, Dr. Joseph Shrager, a professor of cardiothoracic surgery at Stanford University School of Medicine, noticed that lung cancer diagnoses were noticeably higher at age 65 than at slightly older or younger... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 7, 2021 Category: General Medicine Source Type: news

Scientists at IRB Barcelona identify a potential target to treat lung cancer
(Institute for Research in Biomedicine (IRB Barcelona)) -As an approach to personalized medicine, the work proposes the HMCES sensor of DNA damage as a target to treat some of the most aggressive types of lung tumors. The results have been published in PLOS Biology. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 7, 2021 Category: International Medicine & Public Health Source Type: news

PHE’s emeritus medical director dies
Public Health England’s emeritus medical director has died four years after being diagnosed with late-stage lung cancer. (Source: HSJ)
Source: HSJ - April 6, 2021 Category: UK Health Source Type: news

Small cell lung cancer: Scientists identify two new approaches for therapy
(University of Cologne) Iron-dependent cell death ferroptosis and cell death by oxidative stress can be activated in small cell lung cancer, and induced by two drugs / publication in 'Nature Communications' (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - April 6, 2021 Category: International Medicine & Public Health Source Type: news

Tislelizumab Plus Chemo Slows Advanced Squamous NSCLC
MONDAY, April 5, 2021 -- For patients with advanced squamous non-small cell lung cancer (sq- NSCLC), adding tislelizumab in combination with chemotherapy is associated with improved progression-free survival (PFS), according to a study published... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 5, 2021 Category: Pharmaceuticals Source Type: news

High expression of cell death genes associated with early death from lung cancer
(Medical College of Georgia at Augusta University) Patients with a high number of genes most associated with pathways that lead to cell death in lung cancer, are at increased risk of dying early from their disease, researchers report. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - April 5, 2021 Category: Biology Source Type: news

Phase III Trial of Durvalumab for Mesothelioma Underway
The U.S. Food and Drug Administration will be closely watching the latest, international phase III clinical trial for unresectable pleural mesothelioma involving the immunotherapy drug durvalumab. FDA approval may be coming soon. “It looks very promising,” Dr. Arkadiusz Dudek, of Regions Hospital Cancer Care Center in St. Paul, Minnesota, told The Mesothelioma Center at Asbestos.com. “The hope is to have the regimen approved by the FDA as front-line therapy. There is a real need today for more options with mesothelioma.” The goal of the randomized trial – officially known as DREAM3R &...
Source: Asbestos and Mesothelioma News - April 1, 2021 Category: Environmental Health Authors: Fran Mannino Source Type: news

How can access to CT lung cancer screening be improved?
Researchers are sounding the alarm yet again that access and adherence to C...Read more on AuntMinnie.comRelated Reading: Medicare urged to update lung cancer screening coverage ACR praises USPSTF's lung cancer screening changes USPSTF's new lung cancer screening guidance lowers starting age How useful is shared decision-making for lung cancer screening? IASLC: Screen nonsmokers for lung cancer, too (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 31, 2021 Category: Radiology Source Type: news

U of M Medical School faculty help lead new VA Lung Cancer Screening and Research Network
(University of Minnesota Medical School) Two researchers from the University of Minnesota Medical School, who also practice at the Minneapolis VA Health Care System, join the Omaha VA Medical Center to lead the Upper Midwest VA Lung Cancer Screening and Research Network as part of a nationwide VA-funded Lung Precision Oncology Program (LPOP). The $4.5 million grant supports an expansion in lung cancer screenings and research among veterans. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 31, 2021 Category: Cancer & Oncology Source Type: news

The IASLC Molecular Database Project: Objectives, challenges and opportunities
(International Association for the Study of Lung Cancer) A new Molecular Database Project initiated by the International Association for the Study of Lung (IASLC) will accelerate the understanding of lung cancer biology, clinical care and care delivery on a global scale and will improve the prognosis and optimal treatment of lung cancer across time and space, according to an editorial in the Journal of Thoracic Oncology, an official journal of the IASLC. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 31, 2021 Category: International Medicine & Public Health Source Type: news

Obesity Tied to Increased Mortality Overall in Patients With Cancer
Risk for death lower for patients with lung cancer, renal cell carcinoma, melanoma with versus without obesity (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 30, 2021 Category: Cancer & Oncology Tags: Dermatology, Gastroenterology, Gynecology, Internal Medicine, Nephrology, Oncology, Pathology, Pulmonology, Radiology, Journal, Source Type: news

How Genes Affect Lung Cancer
Lung cancer and genes are related, but probably not in the way you might think. (Source: WebMD Health)
Source: WebMD Health - March 30, 2021 Category: Consumer Health News Source Type: news

Lung Cancer: UVA health expert helps develop new national screening guidelines
(University of Virginia Health System) Through his role on the US Preventive Services Task Force, UVA Health's Li Li, MD, Ph.D., MPH, has helped develop new lung cancer screening guidelines that expand screenings to more high-risk patients. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 30, 2021 Category: International Medicine & Public Health Source Type: news

Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full deta...
Source: Roche Media News - March 26, 2021 Category: Pharmaceuticals Source Type: news

Roche receives positive CHMP opinion for Tecentriq as a first-line monotherapy treatment for people with a type of metastatic non-small cell lung cancer
Basel, 26 March 2021 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of Tecentriq® (atezolizumab) as a first-line (initial) treatment for adults with metastatic non-small cell lung cancer (NSCLC) whose tumours have high PD-L1 expression*, with no epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK) genomic tumour aberrations. Based on this recommendation, a final decision regarding the approval of Tecentriq in this disease setting, along with the full deta...
Source: Roche Investor Update - March 26, 2021 Category: Pharmaceuticals Source Type: news

Risk prediction to reduce minority disparities in USPSTF lung cancer screening guidelines
(American Roentgen Ray Society) According to ARRS' American Journal of Roentgenology (AJR), updated United States Preventive Services Task Force (USPSTF) lung cancer screening (LCS) guidelines based solely on age, pack-years, and quit-years perpetuate eligibility disparities among racial and ethnic minorities, although incorporating certain risk prediction models may help reduce such inequalities. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 26, 2021 Category: International Medicine & Public Health Source Type: news

UCLA researchers receive $6 million from NIH to explore new pancreatic cancer therapies
A team of researchers from theUCLA Jonsson Comprehensive Cancer Center has been awarded two research grants totaling $6 million from the National Institutes of Health to identify new ways to treat pancreatic cancer.Pancreatic cancer is the third leading cause of cancer-related mortality in the United States, accounting for more than 47,000 deaths annually. Only 1 in 10 people diagnosed with this particularly aggressive disease live beyond five years, and most therapies — including conventional chemotherapies, targeted therapies and immunotherapies — are unsuccessful in treating it.“Pancreatic cancer is on...
Source: UCLA Newsroom: Health Sciences - March 25, 2021 Category: Universities & Medical Training Source Type: news

Second drug targeting KRASG12C shows benefit in mutated non-small-cell lung cancer
(European Society for Medical Oncology) Clinical activity with a second drug inhibiting KRASG12C confirms its role as a therapeutic target in patients with advanced non-small-cell lung cancer (NSCLC) harbouring this mutation, according to results from a study with the KRASG12C inhibitor adagrasib reported at the European Lung Cancer Virtual Congress 2021. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - March 25, 2021 Category: Cancer & Oncology Source Type: news

Potential COVID-19 treatment identified in UCLA-led lab study
This study identified a new potential therapy that could help the global fight against COVID-19 and support populations that have been disproportionately affected by this deadly disease.”Drugs are categorized as small molecules when their individual molecules are tiny enough that they can penetrate to where they are needed. The researchers screened 430 drugs from among the approximately 200,000 compounds in CNSI ’sMolecular Screening Shared Resource libraries. They identified 34  that demonstrated at least some ability to halt the coronavirus, and eight that did so at relatively lower doses, before zeroing...
Source: UCLA Newsroom: Health Sciences - March 24, 2021 Category: Universities & Medical Training Source Type: news

Covid-19: Lung cancer referrals fell by a THIRD during the pandemic
Figures analysed by Cancer Research UK show that between March and January, referrals for lung cancer fell by 34 per cent. Dr Neil Smith said the stay at home message delayed diagnoses. (Source: the Mail online | Health)
Source: the Mail online | Health - March 24, 2021 Category: Consumer Health News Source Type: news

FDA clears Optellum's lung cancer diagnosis software
The U.S. Food and Drug Administration (FDA) has cleared artificial intelligenc...Read more on AuntMinnie.comRelated Reading: Optellum, Mirada present lung cancer study at RSNA 2017 Optellum unveils lung cancer analysis software (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 23, 2021 Category: Radiology Source Type: news

CXR-Age algorithm assesses biological age on chest radiographs
A deep-learning algorithm called CXR-Age can estimate a patient's biologica...Read more on AuntMinnie.comRelated Reading: AI predicts cardiovascular risk on routine chest CT AI helps predict lung cancer screening eligibility AI can spot smokers at high risk of cancer on x-rays AI reveals prognostic information in chest x-rays Deep learning shows promise for bone age assessment (Source: AuntMinnie.com Headlines)
Source: AuntMinnie.com Headlines - March 23, 2021 Category: Radiology Source Type: news